Zach Pochiro (F) from Fort Wayne Komets to Allen Americans
Date: 07/12/2022
Player: Zach Pochiro (F)
From: Fort Wayne Komets
To: Allen Americans
Source: You need a free account to view Transfer URL Sign In/Up
Date: 07/12/2022
Player: Zach Pochiro (F)
From: Fort Wayne Komets
To: Allen Americans
Source: You need a free account to view Transfer URL Sign In/Up
Date: 07/12/2022
Player: Justin Scott (F)
From: Cleveland Monsters
To: Colorado Eagles
Source: You need a free account to view Transfer URL Sign In/Up
Date: 07/12/2022
Player: Dylan McLaughlin (F)
From: Rockford IceHogs
To: Springfield Thunderbirds
Source: You need a free account to view Transfer URL Sign In/Up
Date: 07/12/2022
Player: Tomas Janci (D)
From: Clermont
To: Valence
Source: You need a free account to view Transfer URL Sign In/Up
This study compares the incidence of SARS-CoV-2 infection in players and staff of the National Basketball Association (NBA) who did vs those who did not receive a COVID-19 vaccine booster dose.
This Viewpoint discusses incorporating indoor air ventilation, filtration, and disinfection measures as part of community-level SARS-CoV-2 transmission reduction efforts.
This JAMA Patient Page describes monkeypox infection, how it is spread, and its symptoms, treatment, and prevention measures.
This Viewpoint summarizes current knowledge of the 2022 monkeypox virus outbreak and the pathology, symptoms, diagnosis, prevention measures, and treatment options for monkeypox infection.
This randomized clinical trial assesses whether high-flow nasal cannula therapy is noninferior to continuous positive airway pressure for time to liberation from respiratory support among acutely ill children clinically assessed to require noninvasive respiratory support in pediatric critical care units.
This Medical News article explores timely topics discussed at the American Society of Clinical Oncology’s 2022 annual meeting.
This Medical News article discusses a recent study comparing SARS-CoV-2 antibody levels among pregnant people and their infants after 2 vs 3 doses of the BNT162b2 (Pfizer-BioNTech) mRNA vaccine.
This Viewpoint posits that to improve the diagnostic process, standards should be set for minimally acceptable diagnostic performance and actionable, timely, and meaningful information should be gained from measurement.
A 59-year-old man had 3 months of unexplained chronic diffuse abdominal pain. Results of upper and lower endoscopy, abdominal-pelvic CT, and urinalysis were unremarkable; hemoglobin level was 8.7 g/dL; peripheral blood smear showed basophilic stippling of erythrocytes; and physical examination showed bluish pigmentation along the gingival margin. What is the diagnosis and what would you do next?
This systematic review, analysis, and process study uses available evidence and expert consensus to provide suggested implications for addressing spirituality in serious illness and health outcomes as part of person-centered, value-sensitive care.
it always comes by at this moment—that taste on the tongue a bit like a copper penny together with odors of lilies and the church’s dank stone if you call all that mere happenstance you’re wrong
This randomized clinical trial compares the efficacy of treatment guided by pharmacogenomic testing vs usual care to determine whether pharmacogenomic testing affects antidepressant medication selection and whether such testing leads to better clinical outcomes among patients with major depressive disorder (MDD).
This serial cross-sectional study used data from the Medicare Patient Safety Monitoring System for 2010 to 2019 to determine the change in the rate of adverse events in hospitalized patients.
In Reply We appreciate the concerns expressed by Dr Stone and colleagues that the commercially available assay for antibodies against the SARS-CoV-2 RBD used in our Research Letter measures total immunoglobulin levels rather than IgG levels. That said, this assay, particularly given its wide availability, has played a critical role in research about vaccines and convalescent immunity. For example, our work using this assay showed poor vaccine immunogenicity in populations at high risk of breakthrough infections... Читать дальше...
In Reply In response to our Viewpoint encouraging the approval of safer and more effective OTC rescue inhalers for asthma, Dr May and colleagues emphasize the increased morbidity and mortality associated with β-agonist overuse in the absence of ICSs. In keeping with recent Global Initiative for Asthma guidelines, we in fact argued that as-needed ICS-FABAs should be preferred to albuterol as optimal OTC rescue therapy. The authors note the problems of albuterol without addressing the case for OTC ICS-FABAs.
In Reply We read the comments by Dr Abe and colleagues, who work in palliative care medicine at a cancer center, as arising from a clinical care model that is quite different from the typical short-term agitated states of individuals with bipolar disorder. The aim of our study was not to demonstrate long-term efficacy or treat underlying illness. The objective was to assess treatment of an acute episode of agitation in patients with bipolar disorder in urgent care settings such as an emergency facility or within an inpatient medical setting.
To the Editor A recent Research Letter reported that 99% of 295 “COVID-confirmed” participants tested positive for antibodies against the SARS-CoV-2 receptor-binding domain (RBD). Testing performed on cross-sectional samples using a total immunoglobulin assay found no association between time after infection and antibody levels. The authors concluded that “although evidence of natural immunity in unvaccinated healthy US adults up to 20 months after confirmed COVID-19 infection is encouraging, it... Читать дальше...
To the Editor A recent Viewpoint recommended that the US Food and Drug Administration (FDA) move fast-acting β2-agonist (FABA) inhalers to over-the-counter (OTC) status, citing the current availability of OTC inhaled epinephrine. Although appreciating the intention of improving access to approved therapies for relief of acute asthma symptoms, we believe this recommendation merits a full consideration of risks and benefits.
To the Editor Dexmedetomidine, a drug with novel mechanisms of action, is used for treatment of delirium in critically ill patients in intensive care units. A recent study investigating sublingual dexmedetomidine efficacy found that this drug reduced mild to moderate agitation in patients with bipolar disorder. We have 2 concerns about interpreting the results of this study.
This study surveyed patients admitted to the emergency department or surgical units at a single hospital to compare an emoji-based pain scale with a conventional numeric rating scale.